Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/29337

Title:	Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.
Authors:	Schmidt, Ralph Majer, Istvan García Román, Natalia Rivas Basterra, Alejandra Grubb, ElizaBeth Medrano López, Constancio View more
Keywords:	Congenital heart disease Cost-effectiveness Palivizumab Prophylaxis Respiratory syncytial virus Spain View more
Issue Date:	19-Dec-2017
Citation:	Health Econ Rev.2017 Dec;(7)1:47
Abstract:	Respiratory syncytial virus (RSV) infection remains one of the major reasons of re-hospitalization among children with congenital heart disease (CHD). This study estimated the cost-effectiveness of palivizumab prophylaxis versus placebo, in Spain, from the societal perspective, using a novel cost-effectiveness model reflecting evidence-based clinical pathways.
PMID:	29260345
URI:	https://hdl.handle.net/20.500.12530/29337
Rights:	openAccess
ISSN:	2191-1991
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:

File	Description	Size	Format
PMC5736509.pdf		893.59 kB	Adobe PDF	View/Open